This.oeminterventional post-marketing study case (H3E-KL-B004, EudraCT# unknown), concerns a 75 year old 
Asiartmate patient. No medical history was reported. Concomitant medications included folic acid, 
cyanocobalamin and dexamethasone as per protocol, nimesulide, paracetamol and fentanyl for pain control, 
ranitidlne and metoclopramide for gastrointestinal protection, doxofylline for cough and magnesium for constipation. 
113 0ct-2009 the = t took the first dose of study drug pemetrexed (Alimta) 800mg intravenous on day 1 of 
21 day cycle for the second line treatment of non-small cell king cancer. Last dose prior to the event was on 14-
Jan-2009. On411,1111111pdays since the last dose of pernetrexecl the patient was admitted to hospital via the 
emergency roc cough and dyspnea which had onset four days previous. Laboratory tests revealed anti-C 
IgF index 10.02 (reference range 0-9), lgM index 9.8 (0-9), C-reactive protein 392mgiL (0-8), white 
count 1.8 x 10A3/uL (4-10) and blood pCO2 50.1 mmHg (35-45). Chest x-ray revealed a diagnosis of 
aggriWitiodtOveumonia in both lungs. The patient received levofioxacin, arnikacin, furosemide, ibuprofen, ranitidine, 
an amino acid complex and human insulin (to be clarified) as corrective treatment. On he patient died 
AS:Am 02.SEP-2014 11:09 AM If a field is blank, there Is no data for that field Page 426  of 661 
FDA - Adverse Event Reporting System (FAERs) 
FOIA Case Report Information 
due to pneumonia and sepsis. No autopsy was performed. The patient was discontinued from the study on the date 
of death. In the opinion of the investigator fatal pneumonia and sepsis were related to pemetrexed. No relatedness 
for protocol procedures was collected.